Paul Kevin Wotton is a businessperson who founded Avenge Bio, Inc. and who has been at the helm of 6 different companies. Currently, he is Chief Executive Officer, President & Director at Obsidian Therapeutics, Inc.
He is also on the board of Vericel Corp., eXIthera Pharmaceuticals, Inc., Cynata Therapeutics Ltd. (former Chairman) and PaxMedica, Inc. and Member of Royal Pharmaceutical Society of Great Britain and Member of Licensing Executives Society.
Paul Kevin Wotton previously occupied the position of President, Chief Executive Officer & Director at Antares Pharma, Inc., Director at Sigilon Therapeutics, Inc., Operations Manager at Kelyniam Global, Inc., Chief Executive Officer of Topigen Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Astellas Institute for Regenerative Medicine, Head-Global Business Development at SkyePharma Plc, Vice President-Business Development for Penwest Pharmaceuticals Co., Vice President-Corporate Development for Eurand NV and Co-Chairman-Integration Management Office at Astellas Pharma US, Inc.
He received a doctorate from The University of Nottingham, an undergraduate degree from the University of London and an MBA from Kingston Business School.